CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement
CytoSorbents regained compliance with Nasdaq's $1.00 minimum bid price requirement after its closing bid price held at or above $1.00 for 10 consecutive trading sessions ending September 21, 2026. Nasdaq's Listing Qualifications Department notified the company on September 22, 2026 that the bid-price matter is now closed. CEO Dr. Phillip Chan noted the company is still working to satisfy the minimum Market Value of Listed Securities requirement under Listing Rule 5550(b)(2) before a December 28, 2026 compliance date.
Key figures
- Mvls compliance deadline
- December 28, 2026
- Min bid price requirement
- $1.00 per share
- Consecutive sessions above 1usd
- 10
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.